Pharmacologic: monoclonal antibodies
Treatment of unresectable/metastatic melanoma.
Binds to cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activation; binding results in augmented T-cell activation and proliferation. Therapeutic Effects: ↓ spread of melanoma.
Adverse Reactions/Side Effects
CNS: fatigue. EENT: immune-mediated ocular disease. GI: IMMUNE-MEDIATED COLITIS, IMMUNE-MEDIATED HEPATITIS, colitis, diarrhea. Derm: IMMUNE-MEDIATED DERMATITIS, INCLUDING TOXIC EPIDERMAL NECROLYSIS, pruritus, rash. Endo: IMMUNE-MEDIATED ENDROCRINOPATHIES, INCLUDING HYPOPITUITARISM, HYPOTHYROIDISM, HYPERTHYROIDISM, ADRENAL INSUFFICIENCY, CUSHING's SYNDROME, AND HYPOGONADISM. Neuro: IMMUNE-MEDIATED NEUROPATHY.
PHYSICAL THERAPY IMPLICATIONS
Examination and Evaluation
For patients who are medically able to begin exercise, implement appropriate resistive exercises and aerobic training to maintain muscle strength and aerobic capacity during cancer chemotherapy or to help restore function after chemotherapy.
Because of numerous immune-mediated problems, use caution during aerobic exercise and endurance conditioning because of potential pulmonary toxicity. Terminate exercise if patient exhibits untoward symptoms (chest pain, shortness of breath, unusual fatigue) or displays other criteria for exercise termination (See Appendix L).
Absorption: IV administration results in complete bioavailability.
Distribution: Crosses the placenta
Metabolism and Excretion: Unknown
Contraindicated in: Lactation: Avoid breast-feeding.